Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$83.86
+1.1%
$83.49
$57.52
$117.19
$32.89B1.444.39 million shs500,664 shs
Haemonetics Corporation stock logo
HAE
Haemonetics
$76.22
+1.4%
$69.66
$55.30
$94.99
$3.66B0.39669,757 shs19,668 shs
HealthEquity, Inc. stock logo
HQY
HealthEquity
$103.34
+1.5%
$100.09
$65.01
$116.65
$8.96B0.49860,020 shs78,411 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$81.26
+2.6%
$82.10
$73.11
$126.89
$5.62B0.121.02 million shs48,130 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
+0.25%-4.98%-4.30%+36.66%-27.05%
Haemonetics Corporation stock logo
HAE
Haemonetics
-2.40%+0.31%+6.07%+34.20%-11.72%
HealthEquity, Inc. stock logo
HQY
HealthEquity
+2.29%-2.80%-8.71%+32.64%+23.33%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
-0.03%-3.26%-2.89%-15.22%+0.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DexCom, Inc. stock logo
DXCM
DexCom
4.8988 of 5 stars
3.55.00.04.72.92.51.9
Haemonetics Corporation stock logo
HAE
Haemonetics
4.8802 of 5 stars
4.52.00.04.32.61.72.5
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.6311 of 5 stars
3.53.00.00.02.32.51.9
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.4547 of 5 stars
3.51.00.04.22.32.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.95
Moderate Buy$98.5017.45% Upside
Haemonetics Corporation stock logo
HAE
Haemonetics
2.91
Moderate Buy$96.8027.01% Upside
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.00
Buy$118.0914.28% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
3.00
Buy$130.5060.60% Upside

Current Analyst Ratings Breakdown

Latest HAE, DXCM, HQY, and LNTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$87.00
6/25/2025
Haemonetics Corporation stock logo
HAE
Haemonetics
Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/23/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $109.00
6/16/2025
DexCom, Inc. stock logo
DXCM
DexCom
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$102.00
6/5/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$112.00 ➝ $125.00
6/5/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$98.00 ➝ $115.00
6/4/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$94.00 ➝ $104.00
6/4/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$112.00 ➝ $117.00
6/4/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$110.00 ➝ $117.00
6/4/2025
HealthEquity, Inc. stock logo
HQY
HealthEquity
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$110.00 ➝ $125.00
5/30/2025
DexCom, Inc. stock logo
DXCM
DexCom
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$104.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.15B7.93$2.27 per share36.90$5.38 per share15.59
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.36B2.69$7.14 per share10.67$16.34 per share4.66
HealthEquity, Inc. stock logo
HQY
HealthEquity
$1.20B7.45$4.31 per share23.96$24.40 per share4.24
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.53B3.67$7.17 per share11.34$15.65 per share5.19
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.3462.6034.091.7712.90%30.05%10.00%7/30/2025 (Estimated)
Haemonetics Corporation stock logo
HAE
Haemonetics
$167.68M$3.3123.0315.121.2512.32%26.37%9.22%8/7/2025 (Estimated)
HealthEquity, Inc. stock logo
HQY
HealthEquity
$96.70M$1.3775.6436.391.579.80%11.01%6.77%9/2/2025 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$312.44M$3.5223.0812.88N/A16.55%36.99%20.55%7/30/2025 (Estimated)

Latest HAE, DXCM, HQY, and LNTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.45N/AN/AN/A$1.13 billionN/A
7/30/2025Q2 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.65N/AN/AN/A$389.69 millionN/A
6/3/2025Q1 2026
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.81$0.97+$0.16$0.61$322.25 million$330.80 million
5/8/2025Q4 2025
Haemonetics Corporation stock logo
HAE
Haemonetics
$1.22$1.24+$0.02$1.17$329.38 million$330.60 million
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
5/1/2025Q1 2025
DexCom, Inc. stock logo
DXCM
DexCom
$0.33$0.32-$0.01$0.27$1.02 billion$1.04 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Haemonetics Corporation stock logo
HAE
Haemonetics
N/AN/AN/AN/AN/A
HealthEquity, Inc. stock logo
HQY
HealthEquity
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.55
1.50
1.32
Haemonetics Corporation stock logo
HAE
Haemonetics
1.12
1.62
0.99
HealthEquity, Inc. stock logo
HQY
HealthEquity
0.50
4.06
4.06
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.49
5.74
5.46

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Haemonetics Corporation stock logo
HAE
Haemonetics
99.67%
HealthEquity, Inc. stock logo
HQY
HealthEquity
99.55%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.32%
Haemonetics Corporation stock logo
HAE
Haemonetics
1.84%
HealthEquity, Inc. stock logo
HQY
HealthEquity
1.50%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
10,300392.11 million390.85 millionOptionable
Haemonetics Corporation stock logo
HAE
Haemonetics
3,02348.04 million47.16 millionOptionable
HealthEquity, Inc. stock logo
HQY
HealthEquity
3,12086.47 million85.18 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70069.19 million67.80 millionOptionable

Recent News About These Companies

Lantheus Seems Worth The (Very Real) Risks
Lantheus Holdings, Inc. (LNTH) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

DexCom stock logo

DexCom NASDAQ:DXCM

$83.86 +0.92 (+1.11%)
As of 10:27 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Haemonetics stock logo

Haemonetics NYSE:HAE

$76.22 +1.09 (+1.44%)
As of 10:27 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HealthEquity stock logo

HealthEquity NASDAQ:HQY

$103.34 +1.51 (+1.48%)
As of 10:27 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$81.26 +2.07 (+2.61%)
As of 10:27 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.